Canadian curler, 20, paralyzed by rare condition: 'She can't move her legs, sit up, or care for herself'
Article content
The story of Brook Aleksic has been shared on fundraising website GoFundMe. Aleksic's former curling coach, Diane Dezura, an Olympic bronze medalist in the sport, organized the fundraiser. As of Monday, it was around $6,000 shy of its $100,000 goal.
Article content
Article content
'Her onset was rapid and severe,' according to the fundraising site. 'She can't move her legs, sit up, or care for herself. The damage to her spinal cord is extensive. While there is hope for some recovery, her path will be long, uncertain and expensive.'
Article content
Article content
Canadian filmmaker Josephine Anderson, who directed Curl Power, filmed Aleksic and her curling teammates 'for much of their teenagehood, as they pursued their dream of becoming national champions,' she told National Post in an email over the weekend. Anderson said audience members connected with Aleksic.
Article content
'Brook always leans towards gratitude and optimism, even when facing difficult moments in her life,' said Anderson. 'When we filmed, Brook was bravely open about struggling with body image and self confidence. We had many, many audience members tell us that Brook was especially inspirational to them.'
Article content
Anderson urged anyone who could help Aleksic and her family 'during this life altering time' to 'please come forward' to offer support.
Article content
Article content
'Becoming paralyzed in a matter of hours is surely the biggest and scariest challenge she's had to face,' Anderson told National Post. 'But somehow Brook is still finding a way to look on the bright side.'
Article content
It's caused by inflammation of the spinal cord, which can damage myelin, the insulating material that covers your nerves, explains a webpage about the condition by Johns Hopkins University School of Medicine. There is no cure, but there are treatments that include high doses of steroids or plasma exchange therapy.
Article content
A third of those with transverse myelitis can have a full or near-full recovery, per Johns Hopkins. Another third can have 'fair recovery' while the final third could 'recover poorly and have major physical disabilities.' Recovery can take up to two years.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
19 minutes ago
- CBC
1 dead, over 40 sick as legionnaires' outbreak spreads in southeast London, Ont.
Social Sharing One person is dead and more than 40 people sick after an outbreak of legionnaires' disease in London, Ont. The Middlesex-London Health Unit, which declared the outbreak, said the cases were reported within the last week. Most of the people with the severe respiratory illness live and/or work within a six-kilometre radius of one another, in the southeast side of the city, officials said. In a statement Tuesday, officials said the health unit is working closely with Public Health Ontario and the Public Health Ontario Laboratories to investigate and try to determine the source of the outbreak. "Environmental sampling of potential sources of legionella is ongoing. Since legionella can be found in many types of cooling systems, the investigation may take time." This is the second outbreak of legionnaires' disease in London since last summer. Last year's outbreak was localized in the city's east end and led to two deaths and 30 total reported infections. "At this time, it is not known whether it [the current outbreak] is the same location as the legionnella outbreak from last year," the health unit said. "However, this is being considered as part of the ongoing investigation." Bacteria found in water sources Legionnaires' disease is caused by legionella bacteria, naturally found in water sources such as hot tubs, cooling towers, hot water tanks, large plumbing systems or parts of air-conditioning systems. Legionella is not transmitted from person to person. If the bacteria are aerosolized or misted into the air (via wind or fans), people may inhale the bacteria and become unwell. Most people exposed to legionella don't get ill, but some may experience Pontiac fever, a mild, flu-like illness that commonly resolves itself. Individuals who are older, have lung problems or are immunocompromised (have a weak immune system) are at greater risk of serious infection. Anyone who develops symptoms such as fever, cough and shortness of breath are encouraged to seek medical attention. All business owners and property managers should ensure all cooling equipment is regularly maintained and sanitized as per the manufacturer's instructions. Although masks can decrease the risk of infection, the health unit is not recommending regular community-wide use of them specifically for the prevention of legionnaire's disease, as the public risk is low.
Globe and Mail
an hour ago
- Globe and Mail
Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?
Shares of Gilead Sciences, Inc. GILD have gained 27.2% in the past six months against the industry 's decline of 2.2%. The stock has also outperformed the sector and the S&P 500 index in this time frame. Gilead Outperforms Industry, Sector & S&P 500 Index It has been an eventful year for GILD so far. The company recently obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV. This groundbreaking injectable therapy marks the first and only twice-yearly pre-exposure prophylaxis (PrEP) option available in the United States. Let's delve further into GILD's strengths and weaknesses to analyze how to play the stock at present. Lenacapavir Approval Boosts GILD's HIV Franchise Gilead has a market-leading portfolio of HIV treatments. Flagship drug Biktarvy accounts for over 51% share of the treatment market in the United States and should maintain momentum. Descovy (FTC 200 mg/TAF 25 mg) for PrEP is also witnessing good uptake. It maintains over 40% market share in the PrEP market in the United States. The recent FDA approval of lenacapavir under the brand name Yeztugo solidifies GILD's HIV portfolio as its other prevention drug, Truvada, faces generic competition. At present, there are two FDA-approved daily oral medications for PrEP — Truvada and Descovy. As the first long-acting injectable PrEP administered just twice a year, Yeztugo addresses persistent barriers, such as challenges with daily oral PrEP, adherence, stigma and healthcare access, which have limited broader PrEP adoption. This approval also represents a paradigm shift in HIV prevention and is expected to catalyze uptake among populations that have historically been underserved by existing prevention tools. Yeztugo has a competitive advantage as it needs to be taken only twice a year, unlike daily oral pills, and addresses a broad population. The European Medicines Agency has also validated the Marketing Authorization Application for twice-yearly lenacapavir for HIV prevention. Livdelzi Strengthens GILD's Liver Disease Portfolio GILD's diverse portfolio also includes drugs for liver, hematology/oncology and inflammation/respiratory diseases. The FDA approval of seladelpar for the treatment of primary biliary cholangitis (PBC) has strengthened GILD's liver disease portfolio and validated its CymaBay acquisition. The drug's initial uptake is encouraging. The candidate was approved under the brand name Livdelzi. Gilead also recently received conditional marketing authorization from the European Commission for seladelpar for the treatment of PBC. Challenges for GILD's Oncology Business Gilead's oncology portfolio, comprising the Cell Therapy franchise and breast cancer drug Trodelvy, has diversified its overall business. However, the Cell Therapy franchise, comprising Yescarta and Tecartus, is currently under pressure due to competitive headwinds in the United States and Europe that are expected to continue in 2025. Breast cancer drug Trodelvy's sales were lower than expected in the first quarter due to inventory dynamics. Nonetheless, Gilead announced positive top-line results from the phase III ASCENT-03 study on Trodelvy, which showed highly statistically significant and clinically meaningful improvement in progression-free survival in patients with first-line metastatic triple-negative breast cancer (mTNBC) who are not candidates for checkpoint inhibitors. The potential launch of anito-cel in multiple myeloma and Trodelvy in first-line mTNBC in 2026 will strengthen the company's oncology business. GILD's Valuation and Estimate Revision According to the price/earnings ratio, GILD's shares currently trade at 13.62x forward earnings, lower than the large-cap pharma industry's average of 15.01X but higher than its mean of 10.52X. Earnings estimates for GILD have moved north in the past 60 days. The bottom-line estimate for 2025 has inched up to $7.92 from $7.91, while that for 2026 has improved to $8.48 from $8.39. Invest in GILD Large biotech companies are generally considered safe havens for investors interested in this sector as they are well-equipped to weather the uncertain macroenvironment. Gilead's efforts to constantly innovate its HIV portfolio should enable it to maintain growth amid competition from GSK plc GSK. The approval of Yeztugo for PrEP is a major boost for the company. GSK's HIV portfolio sales are being driven by strong patient demand for Cabenuva, Apretude and Dovato. GILD has also collaborated with Merck MRK to evaluate the investigational combination of islatravir and lenacapavir for the treatment of HIV. Gilead's strategic deals and acquisitions to diversify its business are encouraging. We recommend the stock to prospective investors, as we believe there is more room for growth following Yeztugo approval, even though Biktarvy sales are expected to be under pressure due to the redesign of Medicare Part D. Another positive factor for both prospective and existing investors is the company's attractive dividend yield. Gilead has been consistently increasing and paying out dividends. The company declared a quarterly dividend of $0.79 per share of common stock for the second quarter of 2025. Its strong cash position (as of March 31, 2025, GILD had $7.9 billion of cash, cash equivalents and marketable debt securities) indicates that the current yield of 2.83% is sustainable. Gilead presently carries a Zacks Rank #2 (Buy). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Zacks' Research Chief Picks Stock Most Likely to "At Least Double" Our experts have revealed their Top 5 recommendations with money-doubling potential – and Director of Research Sheraz Mian believes one is superior to the others. Of course, all our picks aren't winners but this one could far surpass earlier recommendations like Hims & Hers Health, which shot up +209%. See Our Top Stock to Double (Plus 4 Runners Up) >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Merck & Co., Inc. (MRK): Free Stock Analysis Report Gilead Sciences, Inc. (GILD): Free Stock Analysis Report
CTV News
an hour ago
- CTV News
New measles exposure site announced in Manitoba
A medical facility in Winkler, Man., was the site of the province's latest measles exposure. In a news release on Monday, the Manitoba government announced a measles exposure at the Winkler Medical Clinic on July 2 from 12:45 p.m. to 3:15 p.m. Those who were at the clinic at this date and time should monitor for symptoms until July 24. Symptoms of measles usually show up seven to 21 days after exposure and initially include fever, runny nose, drowsiness, irritability, red eyes, and small white spots on the inside of the mouth or throat. Several days of the first symptoms appear, a red blotchy rash develops on the face and moves down the body. Public health asks anyone who was at this clinic during the time of exposure to check their immunization records and ensure they are up to date on the measles vaccine. It also recommends that if you were exposed to the measles, born in 1970 or later, and have never gotten a measles vaccine or infection, then you should get immunized, watch for symptoms and try to reduce exposure to other people. Those who should not get the measles vaccine include infants under the age of six months, pregnant women and people with weakened immune systems. The latest provincial update shows there's been 116 confirmed cases of measles in Manitoba so far this year.
